CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 160 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,517,601 | -17.7% | 164,157 | +1.5% | 0.00% | 0.0% |
| Q2 2023 | $5,488,144 | -7.6% | 161,749 | -2.0% | 0.00% | 0.0% |
| Q1 2023 | $5,939,147 | -21.1% | 165,068 | -2.3% | 0.00% | -50.0% |
| Q4 2022 | $7,531,840 | +64.6% | 168,989 | +3.8% | 0.00% | +100.0% |
| Q3 2022 | $4,575,000 | +13.4% | 162,782 | +8.8% | 0.00% | 0.0% |
| Q2 2022 | $4,033,000 | -23.0% | 149,585 | -2.7% | 0.00% | 0.0% |
| Q1 2022 | $5,236,000 | -11.7% | 153,703 | +0.2% | 0.00% | 0.0% |
| Q4 2021 | $5,930,000 | -36.4% | 153,460 | -11.2% | 0.00% | -50.0% |
| Q3 2021 | $9,327,000 | +139.5% | 172,746 | +48.4% | 0.00% | +100.0% |
| Q2 2021 | $3,894,000 | +283.6% | 116,435 | +136.4% | 0.00% | – |
| Q1 2021 | $1,015,000 | +12.4% | 49,253 | -4.4% | 0.00% | – |
| Q4 2020 | $903,000 | +222.5% | 51,538 | +173.4% | 0.00% | – |
| Q3 2020 | $280,000 | +122.2% | 18,849 | -26.1% | 0.00% | – |
| Q1 2019 | $126,000 | – | 25,521 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
| Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
| TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
| ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
| 5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
| COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
| RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
| Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
| Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
| Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |